Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer

Combination therapy with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and an aromatase inhibitor (AI) for first-line treatment of postmenopausal women with advanced breast cancer (ABC) has demonstrated improvement in progression-free survival (PFS) over AI monotherapy without adding substan...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahtani, Reshma L, Vogel, Charles L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324609/
https://www.ncbi.nlm.nih.gov/pubmed/30655702
http://dx.doi.org/10.2147/CMAR.S186658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324609/
https://www.ncbi.nlm.nih.gov/pubmed/30655702
http://dx.doi.org/10.2147/CMAR.S186658

Ejemplares similares